Population-based survival for cancer patients in Saudi Arabia for the years 2005–2009

AbstractThe Saudi Cancer Registry reported in 2007 the 5-year observed survival for the most common cancer sites for the years 1994–2004. In this report we looked at the cancer survival in the period 2005–2009 and evaluated the trend over the 15 years period from 1994 to 2009. Cases of the top 14 cancer sites reported by the population based Saudi Cancer Registry from 1 January 2005 to December 31, 2009, were submitted for survival analysis. The vital status of those patients was collected. Analysis of survival for the above period was compared with the prior reported 2 periods (1994–1999, 2000–2004). In addition, analysis was done according to age, sex, disease stage and the province. Data of 25,969 patients of the commonest cancer sites were submitted. Of those 14,146 patients (54%) had complete demographic data available and vital status was reported. Thyroid cancer had the highest 5- year observed survival of 94% (95% confidence interval (CI) 93–95%)), followed by Breast (72%, 95% CI 71–74%). In hematological malignancies, Hodgkin’s Lymphoma had the highest 5-year survival of 86% (95% CI 84–88%). Survival rates has improved in most of the cancers sites for the studied periods except for lung, uterine and Hodgkin’s lymphoma which plateaued. Our study confirms a steady improvement in the 5-year observed survival over time for the majority of cancers. Our survival data were comparable to western countries. This data should be used by policy makers to improve on cancer care in the kingdom.

Download Full-text

Cancer Survival in Saudi Arabia 2005-2009: Analysis of the Population-based Saudi Cancer Registry

10.21203/rs.3.rs-455335/v1 ◽

2021 ◽

Author(s):

Mohamed Aseafan ◽

Edward Devol ◽

Mahmoud AlAhwal ◽

Riad Souissi ◽

Reham Sindi ◽

...

Keyword(s):

Cancer Registry ◽

Survival Data ◽

Hodgkin’S Lymphoma ◽

Cancer Survival ◽

Demographic Data ◽

Survival Rates ◽

Population Based ◽

Hodgkin's Lymphoma ◽

Disease Stage ◽

Vital Status

Abstract The Saudi Cancer Registry reported in 2007 the 5-year observed survival for the most common cancer sites for the years 1994-2004. In this report we looked at the cancer survival in the period 2005-2009 and evaluated the trend over the 15 years period from 1994-2009. Cases of the top 14 cancer sites reported by the population based Saudi Cancer Registry from 1 January 2005 to December 31, 2009 were submitted for survival analysis. The vital status of those patients was collected. Analysis of survival for the above period was compared with the prior reported 2 periods (1994-1999, 2000-2004). In addition, analysis was done according to age, sex, disease stage and the province. Data of 25,969 patients of the commonest cancer sites were submitted. Of those 14,146 (54%) had complete demographic data available and vital status was reported. The observed 5-year survival for the 14,146 patients analyzed was 66%. Thyroid cancer had the highest 5- year observed survival of 94% (standard Error (SE) 0.0062), followed by Breast (72%, SE 0.0085). In hematological malignancies, Hodgkin’s Lymphoma had the highest 5-year survival of 86% (SE 0.0116). Survival rates has improved in most of the cancers sites for the studied periods except for lung, uterine and Hodgkin’s lymphoma which plateaued. Our study confirms a steady improvement in the 5-year observed survival over time for the majority of cancers. Our survival data were comparable to western countries. This data should be used by policy makers to improve on cancer care in the kingdom.

Download Full-text

Interpreting Survival Differences and Trends

Tumori Journal ◽

10.1177/030089169708300105 ◽

1997 ◽

Vol 83 (1) ◽

pp. 9-16 ◽

Cited By ~ 26

Author(s):

Franco Berrino ◽

Andrea Micheli ◽

Milena Sant ◽

Riccardo Capocaccia

Keyword(s):

Early Diagnosis ◽

Survival Data ◽

Survival Rates ◽

Relative Survival ◽

Cancer Registries ◽

Population Based ◽

Disease Stage ◽

Definition Of ◽

Survival Differences ◽

Over Time

Since 1990 a concerted action between European population-based cancer registries (the EUROCARE project) has been carried out with the aims of establishing whether there are differences in cancer patient survival in Europe, and the reasons for such differences. Survival differences actually exist for cancer sites for which the stage of disease at diagnosis is the major prognostic factor (such as breast, stomach and colon cancer). However, for most cancer sites, survival increases over time and the survival rates of different countries tend to converge towards higher values. Interpreting survival differences and trends is not an easy task. Longer survival may be achieved by postponing death through better treatment or by anticipating diagnosis. However, an earlier diagnosis may or may not make a treatment more effective in postponing death. The computation of stage-specific or stage-adjusted survival is not sufficient for interpretation of survival differences, because staging procedures change over time and may vary in different hospitals and countries. In addition to an early diagnosis and more effective treatment, a number of factors may bias survival estimates. They may be classified into factors that can be controlled in the analysis (at least partially), such as mortality from other causes, demographic factors, epoch of diagnosis, different statistical methodology, and factors depending on the validity of cancer registry data, such as definition of the illness, exhaustiveness and quality of registration, completeness of follow-up, definition of the date of diagnosis, and definition of disease stage including the diagnostic procedure used to establish stage. To help disentangle the effects of early diagnosis and better treatment, several statistical approaches are being developed: multivariate analysis on relative survival data, new modeling analysis to separately estimate the proportion of cured patients and the length of survival for those patients destined to die, and the standardized collection of information on stage at diagnosis and staging procedures.

Download Full-text

Treatment and outcome in non-Hodgkin's lymphoma patients with and without prevalent diabetes mellitus in a population-based cancer registry

Journal of Geriatric Oncology ◽

10.1016/j.jgo.2011.06.001 ◽

2011 ◽

Vol 2 (4) ◽

pp. 239-245 ◽

Cited By ~ 1

Author(s):

T.T.W. van Herpt ◽

S.A.M. van de Schans ◽

H.R. Haak ◽

D.J. van Spronsen ◽

M.W. Dercksen ◽

...

Keyword(s):

Diabetes Mellitus ◽

Cancer Registry ◽

Hodgkin’S Lymphoma ◽

Population Based ◽

Hodgkin's Lymphoma ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

Lymphocyte-Rich Classical Hodgkin's Lymphoma: Clinical Presentation and Treatment Outcome in 100 Patients Treated Within German Hodgkin's Study Group Trials

Journal of Clinical Oncology ◽

10.1200/jco.2005.17.970 ◽

2005 ◽

Vol 23 (24) ◽

pp. 5739-5745 ◽

Cited By ~ 65

Author(s):

Alexander Shimabukuro-Vornhagen ◽

Heinz Haverkamp ◽

Andreas Engert ◽

Leopold Balleisen ◽

Peter Majunke ◽

...

Keyword(s):

Treatment Outcome ◽

Hodgkin’S Lymphoma ◽

Clinical Presentation ◽

Survival Rates ◽

Current Treatment ◽

Hodgkin's Lymphoma ◽

Disease Stage ◽

Study Group ◽

Treatment Regimens ◽

Histologic Subtypes

Purpose To investigate the clinical characteristics and treatment outcome of patients with lymphocyte-rich classical Hodgkin's lymphoma (LRCHL) compared with other histologic subtypes of Hodgkin's lymphoma (HL). Patients and Methods From a total of 2,715 patients with biopsy-proven HL treated within the trials HD7 to HD12 of the German Hodgkin's Study Group, 100 patients (4%) with LRCHL, 145 patients (5%) with lymphocyte-predominant HL (LPHL), 1,688 patients (62%) with nodular sclerosis, 731 patients (27%) with mixed cellularity, and 23 patients (1%) with lymphocyte depletion were identified. Patients with LRCHL had a median age of 38 years (range, 16 to 74 years). Results Compared with other histologic subtypes, patients with LRCHL are, on average, older and usually present with early stages of disease (stage I, 34%; stage II, 46%). The median time of follow-up was 32.2 months (95% CI, 28.2 to 37.0 months). Complete and partial remission was achieved in 96 patients (96%) and four patients (4%), respectively, with LRCHL. The event-free and overall survival rates were 97% (95% CI, 96.7% to 96.9%) and 97% (95% CI, 96.8% to 97.0%), respectively, at 30 months. Only three patients died; all of the deaths were caused by treatment-related toxicities. Conclusion LRCHL is a distinct subtype of CHL, with features of CHL and LPHL, and is a rare entity accounting for only 4% of HLs. LRCHL has a different pattern of clinical presentation and age and sex distribution than other CHLs. It is associated with an excellent prognosis if treated with current treatment regimens. When treating patients with LRCHL, great attention should be paid to avoid acute toxicities.

Download Full-text

German oncology certification system for colorectal cancer – relative survival rates of a single certified centre vs. national and international registry data

Innovative Surgical Sciences ◽

10.1515/iss-2021-0002 ◽

2021 ◽

Vol 0 (0) ◽

Author(s):

Maximilian Richter ◽

Lena Sonnow ◽

Amir Mehdizadeh-Shrifi ◽

Axel Richter ◽

Rainer Koch ◽

...

Keyword(s):

Colorectal Cancer ◽

Rectal Cancer ◽

International Comparison ◽

Cancer Registry ◽

Survival Data ◽

Survival Rates ◽

Relative Survival ◽

Registry Data ◽

Cancer Registry Data ◽

Colon And Rectal Cancer

Abstract Objectives To evaluate how the certification of specialised Oncology Centres in Germany affects the relative survival of patients with colorectal cancer (CRC) by means of national and international comparison. Methods Between 2007 and 2013, 675 patients with colorectal cancer, treated at the Hildesheim Hospital, an academic teaching hospital of the Hannover Medical School (MHH), were included. A follow-up of the entire patient group was performed until 2014. To obtain international data, a SEER-database search was done. The relative survival of 148,957 patients was compared to our data after 12, 36 and 60 months. For national survival data, we compared our rates with 41,988 patients of the Munich Cancer Registry (MCR). Results Relative survival at our institution tends to be higher in advanced tumour stages compared to national and international cancer registry data. Nationally we found only little variation in survival rates for low stages CRC (UICC I and II), colon, and rectal cancer. There were notable variations regarding relative survival rates for advanced CRC tumour stages (UICC IV). These variations were even more distinct for rectal cancer after 12, 36 and 60 months (Hildesheim Hospital: 89.9, 40.3, 30.1%; Munich Cancer Registry (MCR): 65.4, 28.7, 16.6%). The international comparison of CRC showed significantly higher relative survival rates for patients with advanced tumour stages after 12 months at our institution (77 vs. 54.9% for UICC IV; raw p<0.001). Conclusions Our findings suggest that patients with advanced tumour stages of CRC and especially rectal cancer benefit most from a multidisciplinary and guidelines-oriented treatment at Certified Oncology Centres. For a better evaluation of cancer treatment and improved national and international comparison, the creation of a centralised national cancer registry is necessary.

Download Full-text

Does access to care play a role in liver cancer survival? The ten-year (2006–2015) experience from a population-based cancer registry in Southern Italy

BMC Cancer ◽

10.1186/s12885-021-07935-0 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Walter Mazzucco ◽

Francesco Vitale ◽

Sergio Mazzola ◽

Rosalba Amodio ◽

Maurizio Zarcone ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Access To Care ◽

Cancer Registry ◽

Health Care Services ◽

Cancer Survival ◽

Developed Countries ◽

Population Based ◽

Easy Access ◽

Net Survival ◽

Poor Access

Abstract Background Hepatocellular carcinoma (HCC) is the most frequent primary invasive cancer of the liver. During the last decade, the epidemiology of HCC has been continuously changing in developed countries, due to more effective primary prevention and to successful treatment of virus-related liver diseases. The study aims to examine survival by level of access to care in patients with HCC, for all patients combined and by age. Methods We included 2018 adult patients (15–99 years) diagnosed with a primary liver tumour, registered in the Palermo Province Cancer Registry during 2006–2015, and followed-up to 30 October 2019. We obtained a proxy measure of access to care by linking each record to the Hospital Discharge Records and the Ambulatory Discharge Records. We estimated net survival up to 5 years after diagnosis by access to care (“easy access to care” versus “poor access to care”), using the Pohar-Perme estimator. Estimates were age-standardised using International Cancer Survival Standard (ICSS) weights. We also examined survival by access to care and age (15–64, 65–74 and ≥ 75 years). Results Among the 2018 patients, 62.4% were morphologically verified and 37.6% clinically diagnosed. Morphologically verified tumours were more frequent in patients aged 65–74 years (41.6%), while tumours diagnosed clinically were more frequent in patients aged 75 years or over (50.2%). During 2006–2015, age-standardised net survival was higher among HCC patients with “easy access to care” than in those with “poor access to care” (68% vs. 48% at 1 year, 29% vs. 11% at 5 years; p < 0.0001). Net survival up to 5 years was higher for patients with “easy access to care” in each age group (p < 0.0001). Moreover, survival increased slightly for patients with easier access to care, while it remained relatively stable for patients with poor access to care. Conclusions During 2006–2015, 5-year survival was higher for HCC patients with easier access to care, probably reflecting progressive improvement in the effectiveness of health care services offered to these patients. Our linkage algorithm could provide valuable evidence to support healthcare decision-making in the context of the evolving epidemiology of hepatocellular carcinoma.

Download Full-text

Aspirin and the Risk of Hodgkin's Lymphoma in a Population-Based Case-Control Study

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djh038 ◽

2004 ◽

Vol 96 (4) ◽

pp. 305-315 ◽

Cited By ~ 43

Author(s):

E. T. Chang ◽

T. Zheng ◽

E. G. Weir ◽

M. Borowitz ◽

R. B. Mann ◽

...

Keyword(s):

Hodgkin’S Lymphoma ◽

Case Control Study ◽

Population Based ◽

Case Control ◽

Hodgkin's Lymphoma ◽

Control Study

Download Full-text

EPID-10. GLIOMA INCIDENCE AND SURVIVAL BY INCOME LEVEL IN THE UNITED STATES GENERAL POPULATION AGES AND ABOVE FROM 2000-2018

Neuro-Oncology ◽

10.1093/neuonc/noab196.343 ◽

2021 ◽

Vol 23 (Supplement_6) ◽

pp. vi87-vi88

Author(s):

Jennifer Murillo ◽

Elizabeth Anyanda ◽

Jason Huang

Keyword(s):

United States ◽

General Population ◽

Survival Data ◽

Survival Rates ◽

The United States ◽

Income Level ◽

Population Based ◽

Research Database ◽

Income Levels ◽

Average Survival

Abstract Gliomas are the most common primary malignant brain tumor in the United States with previous studies showing the incidence varied by age, sex, and race or ethnicity. Survival after diagnosis has also been shown to vary by these factors. Also, socioeconomic status and its association with various cancers have also been studied at length over time. PURPOSE: The purpose of our research was to quantify the differences in incidence and survival rates of gliomas in 15 years and older by income level. METHODS: This population-based study obtained incidence and survival data from the Incidence-SEER Research Database the general population. Average age incidence were generated by glioma groups and grouped by income levels. Survival rates were generated by overall glioma diagnosis grouped by observed survival at 12, 24, 36, 48 and 60 months and by again by income levels. The analysis included 94,207 patients with glioma diagnosed in those aged 15 years or older. RESULTS: Overall, 94, 207 patients diagnosed with glioma were analyzed. Of these, 1,089 (1.16%) fell into the < $35k group, 1,684 (1.79%) in the $35k-$40k group, 3,473 (3.69%) in the $40k-$45k group, 5,647 (5.99%) in the $45k-$50k group, 7,138 (7.58%) in the $50k-$55k group, 6,468 (6.87%) in the $55k-$60k group, 15,348 (16.29%) in the $60k-$65k group, 13,216 (14.03%) in the $65k-$70k group, 9,035 (9.59%) in the $70k-$75k group, and 31,109 (33.02%) fell in > $75k group. The data was also broken further down into survivability showing average survival. CONCLUSION: Incidence of glioma and 12, 24, 36, 48 and 60 month survival rates after diagnosis vary significantly by income level with higher income level greater than $75,000+ having higher incidence and higher survival rates compared with lower income levels. Further research is needed to help determine risk factors and barriers to care to help reveal health disparities.

Download Full-text